ARCT
Price
$17.85
Change
+$1.09 (+6.50%)
Updated
Sep 5 closing price
Capitalization
484.71M
59 days until earnings call
RGNX
Price
$9.71
Change
+$0.29 (+3.08%)
Updated
Sep 5 closing price
Capitalization
490.49M
59 days until earnings call
Interact to see
Advertisement

ARCT vs RGNX

Header iconARCT vs RGNX Comparison
Open Charts ARCT vs RGNXBanner chart's image
Arcturus Therapeutics Holdings
Price$17.85
Change+$1.09 (+6.50%)
Volume$511.46K
Capitalization484.71M
REGENXBIO
Price$9.71
Change+$0.29 (+3.08%)
Volume$611.16K
Capitalization490.49M
ARCT vs RGNX Comparison Chart in %
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. RGNX commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (ARCT: $17.85 vs. RGNX: $9.71)
Brand notoriety: ARCT and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 93% vs. RGNX: 99%
Market capitalization -- ARCT: $484.71M vs. RGNX: $490.49M
ARCT [@Biotechnology] is valued at $484.71M. RGNX’s [@Biotechnology] market capitalization is $490.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARCT and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 6 TA indicator(s) are bullish while RGNX’s TA Score has 7 bullish TA indicator(s).

  • ARCT’s TA Score: 6 bullish, 4 bearish.
  • RGNX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а +4.94% price change this week, while RGNX (@Biotechnology) price change was +8.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

RGNX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($490M) and ARCT($485M) have the same market capitalization . RGNX YTD gains are higher at: 25.614 vs. ARCT (5.186). ARCT has higher annual earnings (EBITDA): -54.54M vs. RGNX (-129.93M). RGNX has more cash in the bank: 323M vs. ARCT (196M). ARCT has less debt than RGNX: ARCT (27M) vs RGNX (77.7M). RGNX has higher revenues than ARCT: RGNX (156M) vs ARCT (110M).
ARCTRGNXARCT / RGNX
Capitalization485M490M99%
EBITDA-54.54M-129.93M42%
Gain YTD5.18625.61420%
P/E RatioN/AN/A-
Revenue110M156M71%
Total Cash196M323M61%
Total Debt27M77.7M35%
FUNDAMENTALS RATINGS
ARCT vs RGNX: Fundamental Ratings
ARCT
RGNX
OUTLOOK RATING
1..100
9112
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
3844
P/E GROWTH RATING
1..100
10022
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (43) in the Pharmaceuticals Major industry is in the same range as RGNX (70) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as RGNX (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as RGNX (98) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

ARCT's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as RGNX (44) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (22) in the Biotechnology industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that RGNX’s stock grew significantly faster than ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTRGNX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 19 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LFGVX42.670.05
+0.12%
Lord Abbett Focused Growth R6
WWIAX12.46N/A
N/A
Westwood Income Opportunity A
IRLSX80.64N/A
N/A
Voya Russell Large Cap Growth Idx Port S
UIVQX13.04N/A
N/A
MFS Intrinsic Value R4
FDECX23.84-0.16
-0.67%
Fidelity Advisor Capital Development C

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RGNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+6.50%
RGNX - ARCT
51%
Loosely correlated
+3.08%
CLDX - ARCT
50%
Loosely correlated
+0.40%
MGNX - ARCT
46%
Loosely correlated
+3.09%
MRNA - ARCT
46%
Loosely correlated
+3.54%
RXRX - ARCT
46%
Loosely correlated
+1.99%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+3.08%
SYRE - RGNX
55%
Loosely correlated
+0.06%
DNLI - RGNX
54%
Loosely correlated
+4.33%
KYMR - RGNX
53%
Loosely correlated
+3.10%
VYGR - RGNX
53%
Loosely correlated
+9.28%
IDYA - RGNX
53%
Loosely correlated
+5.15%
More